NCT05933447 - Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2023

Primary Completion Date

July 28, 2023

Study Completion Date

July 28, 2023

Conditions

Healthy

Interventions

DRUG

Rodatristat Ethyl

Oral, Tablet, 300 mg QD, 300 mg BID, 600 mg BID, 900 mg BID, 900 mg QD

DRUG

Moxifloxacin

Oral, Tablet, 400 mg QD

DRUG

Placebo for Rodatristat

Oral, Tablet, O mg QD, 0 mg BID

DRUG

Placebo for Moxifloxacin

Oral, Tablet, 0 mg QD

Trial Locations (1)

Altasciences Clinical Kansas, Inc., Overland Park